Headway’s valuation hits $2.3B after closing its Series D: The startup tackles two big problems in the mental health space. Investors are paying close attention.
Humana’s CenterWell to open senior primary care clinics at Walmart stores: Despite recent headwinds in the retail primary care space, we think CenterWell’s deal with Walmart will prove to be symbiotic.
Mayo Clinic, Epic, Abridge develop genAI tool for nurses: The platform will help relieve nurses’ administrative burden, but they still have concerns about AI in healthcare.
40% of drugs approved in the past decade will be blockbusters: We unpack a new forecast of projected drug sales and explore if forthcoming industry headwinds will be enough to curb revenue growth.
Hims & Hers adds longtime Novo exec to its board: Here’s what the appointment tells us about Hims & Hers’ ambitions in the GLP-1 space.
PwC expects healthcare costs to grow 8% in 2025: Below, we detail the primary drivers and how we expect health insurers to combat them.
Physician burnout is declining: While there’s modest improvement in burnout rates, employers who staff doctors need to make them feel more valued at work.
GCI Group rolls out health influencer marketing service: We unpack the details of the new offering from the healthcare communications agency and explore why it could be positioned to succeed in this increasingly crowded space.
Big Pharma’s missed opportunity to connect with consumers in local markets: Most drugmakers don’t have country-specific mobile apps or social media accounts.
Teladoc partners with Brightline for pediatric mental healthcare: Here’s why Teladoc’s tie-up with the virtual behavioral health startup makes perfect sense from both a patient acquisition and financial standpoint.
Boehringer Ingelheim, GoodRx offer cheaper version of Humira biosimilar: Increased competition in the space should help reduce prices for cash-strapped Americans, but not fast enough.
A lifeline for digital therapeutics? A proposal to reimburse doctors for treating patients through digital therapies could help a small group of DTx players, but it might be too late for struggling companies.
Where patients get GLP-1 prescriptions: In-person clinics with familiar doctors are the current preference. However, we still see a huge market opportunity for online providers.
UnitedHealth Group records $4.2B in Q2 profit: We unpack the financials behind UnitedHealth Group’s big Q2 and explore why reining in the influence of massive healthcare companies is so difficult.
Caregivers in the US are burned out: We explore the opportunity healthcare and pharma brands have to create marketing strategies specifically tailored to caregivers.
Docs use genAI to appeal denied prior authorizations: Here’s why physicians are turning to the tech for appeals and where we think the prior authorization standoff between insurers and providers is headed.
Pfizer is developing a once-a-day oral GLP-1: Two drugmakers control the weight loss drug market—for now. Here's who could benefit the most from more players in the space.
FDA revises guidance to help drug- and device-makers address social media misinformation: But we’re not sure the regulator has the appetite to take on more authority related to healthcare and pharma social media ads.
FTC to sue PBMs over drug pricing tactics: Could pharmacy benefit managers’ power over negotiating drug prices start to diminish?
GLP-1 drugs from Novo, Lilly go head to head in clinical study: We explore the findings and their impact on the broader weight loss drug market.